A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide
| Autor: | Petrylak, D.P., Vaishampayan, U.N., Patel, K.R., Higano, C.S., Albany, C., Dawson, N.A., Mehlhaff, B.A., Quinn, D.I., Nordquist, L.T., Wagner, V.J., Siegel, J., Trandafir, L., Sartor, O. |
|---|---|
| Zdroj: | In ESMO Open April 2021 6(2) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|